IGC Pharma develops drug candidates for Alzheimer's disease, with its lead candidate in clinical trials for agitation linked to the condition. It last closed at $0.18 on Nov 17, up 3.08% on the day. IGC last reported earnings on Thu, Aug 13, 2026.
Only 1 firm rated IGC in the past 90 days, not enough for a consensus
Average 12-month target
$6.00
▲ 3160.9% upside
Based on 1 analyst who set a price target on IGC in the past 90 days. The average target is $6.00, with a high of $6.00 and a low of $6.00, compared with the last close of $0.18.
Low $6.00Avg $6.00High $6.00
Blue marker: last close $0.18
Highest target$6.00
Average target$6.00
Lowest target$6.00
Latest rating changes
Ascendiant CapitalTarget raised
Aug 26Buy$5.50 → $6
Ascendiant CapitalMaintained
Jun 8Buy$5.50
Date
Firm
Action
Rating
Price target
Aug 26
Ascendiant Capital
Target raised
Buy
$5.50 → $6
Jun 8
Ascendiant Capital
Maintained
Buy
$5.50
Loading…
Technical Analysis
IGC · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold
The stock is 12% below its 20 day and 34% below its 50 day average. It is 49% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 34), near oversold. The nearest support is the Pivot at $0.18, and the nearest resistance the Pivot R1 at $0.19.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 9.6%/day
Key levels
$0.3752 week high+105.6%
$0.27200 day average+50.0%
$0.26100 day average+44.4%
$0.2550 day average+38.9%
$0.2120 day average+16.7%
$0.21Swing high (Nov 9)+16.7%
$0.19Pivot R1+5.6%
$0.18Pivot+0.0%
$0.18Pivot S1+0.0%
$0.18Swing low (Nov 5)+0.0%
$0.18Last close
$0.0852 week low−55.6%
Indicators
RSI (14)
33.57
Weak, oversold below 30
Neutral
MACD
-0.02
Below its signal line
Bearish
Stochastic
58.8
Middle of its range
Neutral
ADX (14)
58.8
Strong downtrend
Williams %R
-37.0
Oversold below −80, overbought above −20
Neutral
CCI (20)
-62.4
Oversold below −100, overbought above 100
Neutral
Rate of change
−3.7%
Change over 10 sessions
Bearish
ATR (14)
$0.02
Typical daily range, 9.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, nearing oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 20.9%/day
Key levels
$0.3752 week high+105.6%
$0.27200 day average+50.0%
$0.26100 day average+44.4%
$0.2550 day average+38.9%
$0.2120 day average+16.7%
$0.21Swing high (Nov 9)+16.7%
$0.19Pivot R1+5.6%
$0.18Pivot+0.0%
$0.18Pivot S1+0.0%
$0.18Swing low (Nov 5)+0.0%
$0.18Last close
$0.0852 week low−55.6%
Indicators
RSI (14)
31.90
Weak, oversold below 30
Neutral
MACD
-0.03
Below its signal line
Bearish
Stochastic
40.6
Middle of its range
Neutral
ADX (14)
23.1
Weak trend
Williams %R
-60.1
Oversold below −80, overbought above −20
Neutral
CCI (20)
-156.1
Oversold below −100, overbought above 100
Oversold
Rate of change
−34.0%
Change over 10 sessions
Bearish
ATR (14)
$0.04
Typical daily range, 20.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for IGC
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how IGC did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow IGC usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How IGC has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IGC is in one of them and how their past IGC trades turned out.
IGC Pharma is a drug development company based in Potomac, Maryland, focused mainly on Alzheimer's disease. Its lead candidate, IGC-AD1, is in a clinical trial for agitation, a behavioral symptom common in people with Alzheimer's dementia. The company is also building MINT-AD, an artificial intelligence data tool meant to support clinicians and researchers in assessing risk in Alzheimer's patients. It does not yet sell pharmaceutical products.